Ever Heard of Iqvia? Its CEO Made $38 Million
By: Wall Street Journal
June 12, 2018
Iqvia Holdings Inc. IQV 0.83% is hardly a household name, but its boss made more last year than the chief executive of Johnson & Johnson —or any other big pharmaceutical or biotech company.
Iqvia doesn’t have some blockbuster drug or cutting-edge genetic treatment. It is a data company that collects prescription sales, medical claims and other patient records, and analyzes that information for drugmakers, insurance companies and governments. It also provides testing services to drug companies.
Last year, the Durham, N.C., company paid its CEO, Ari Bousbib, $38 million. J&J, the largest U.S. pharmaceutical company by revenue, paid its CEO, Alex Gorsky, $29.8 million in 2017. J&J had about $76 billion in revenue in 2017, Iqvia’s was about $8 billion.
The two companies delivered similar shareholder gains last year. J&J’s stock-price appreciation plus dividends returned 24.4% to investors, while the smaller company returned 28.7%.
Some articles require a paid subscription.
